Table 1 Clinical data for 218 patients

From: IGF-IR: a new prognostic biomarker for human glioblastoma

Age (years)

Median (range)

64 (21–81)

Gender

Female/male

97/121

Multifocality

No

162

Yes

45

Missing

11

Date of surgery

Median (range)

1999 (1988–2006)

Surgical resection

Complete

63

Partial

140

Missing

15

Adjuvant therapy

No

4

Radiotherapy a

142

 Standard protocol (dose (Gy)/number of fractions) (median (range)): 60 (55–66)/30 (28–40)

81

 Incomplete protocolb (dose (Gy)/number of fractions) (median (range)): 32 (20–54)/10.5 (10–27)

17

 Missing

44

Radiotherapy+temozolomide a

26

 Radiotherapy

 

Standard protocol (dose (Gy)/number of fractions) (median (range)): 60 (54–64)/30 (20–33)

21

Incomplete protocolb (dose (Gy)/number of fractions) (median (range)): 39.5 (39–40)/16.5 (13–20)

2

Missing

3

 Temozolomide

 

Concomitant (=every day during radiotherapy)

 

 Dose (mg m−2 day−1): 75

12

 Missing

14

Adjuvant

 

 Dose (mg m−2 day−1)/number of cycle (median (range)): 187.5 (100–200)/3 (1–9)

15

 Missing

11

Othersc

11

Missing

35

Follow-up (months)

Median (range)

8 (0–90)

Death

77.1%

Median survival (months)

10

  1. The table displays the numbers (or percentage) of cases except when other features are indicated (such as median and range).
  2. aConsidered as standard therapies.
  3. bFor reasons such as clinical degradation of patients.
  4. cIncluding non-standard therapies for GBM patients, such as chemotherapy alone or combined with radiotherapy or palliative management.
Back to article page